Fatty acids, C9-13-neo-, barium salts

Repeated dose toxicity: oral

Administrative data

Endpoint:

repeated dose toxicity: oral

Type of information:

experimental study

Adequacy of study:

supporting study

Reliability:

4 (not assignable)

Rationale for reliability incl. deficiencies:

other: Secondary Literature.

Data source

Reference

Reference Type:

secondary source

Title:

Neoacids C5 to C28 Category Analysis Report for the U.S. High Production Volume Chemical Challenge Program

Author:

ExxonMobil Biomedical Sciences, Inc.

Year:

2006

Materials and methods

Principles of method if other than guideline:

Five male and five female rats were exposed to 0; 10; 55; or 300 mg/kg/dayfatty acids, C9-C13 neo (CAS# 68938-07-8) by oral gavage for 28 consecutive days (Shell Internationale Petroleum Maatschappij, 1994). There were no mortalities. Increased salivation was observed after dosing in rats receiving 300 mg/kg. No treatment related changes were observed in body weight, food consumption, hematology, or clinical chemistry. In males receiving 300 mg/kg, kidney weight increased and necropsy revealed an abnormal appearance of the kidney. A dose-related hyaline droplet was noted in males at all treatment levels. The findings in the kidney of the treated males are species and sex specific and not considered relevant to humans. The NOAEL in this study was 300 mg/kg.

Test material

Test material information

Constituent 1

Reference substance name:

Fatty acids, C9-13-neo-

EC Number:

273-114-3

EC Name:

Fatty acids, C9-13-neo-

Cas Number:

68938-07-8

Molecular formula:

C9H18O2 to C13H26O2

IUPAC Name:

Fatty acids, C9-13-neo-

Results and discussion

Effect levels

Dose descriptor:

NOAEL

Effect level:

300 mg/kg bw/day (nominal)

Sex:

male/female

Target system / organ toxicity

Critical effects observed:

not specified

Applicant's summary and conclusion

Executive summary:

Five male and five female rats were exposed to 0; 10; 55; or 300 mg/kg/day fatty acids, C9-C13 neo (CAS# 68938-07-8) by oral gavage for 28 consecutive days (Shell Internationale Petroleum Maatschappij, 1994). There were no mortalities. Increased salivation was observed after dosing in rats receiving 300 mg/kg. No treatment related changes were observed in body weight, food consumption, haematology, or clinical chemistry. In males receiving 300 mg/kg, kidney weight increased and necropsy revealed an abnormal appearance of the kidney. A dose-related hyaline droplet was noted in males at all treatment levels. The findings in the kidney of the treated males are species and sex specific and not considered relevant to humans. The NOAEL in this study was 300 mg/kg.